Promising avenues of therapeutics for bipolar illness

Dialogues in Clinical Neuroscience

Volumn 10, Issue 2, 2008, Pages 193-201

  Post, Robert M ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Bipolar Collaborative Network   (United States)

^c NONE   (United States)

Author keywords

Anticonvulsant; Antioxidant; Brain derived neurotrophic factor; Comorbidity; Deep brain stimulation; Glutamate antagonist; Neuropeptide; Repeated transcranial magnetic stimulation; Substance abuse; Vagal nerve stimulation

Indexed keywords

ACETYLCYSTEINE; AGOMELATINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; FLUOXETINE; FOLIC ACID; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; ICOSAPENTAENOIC ACID; INOSITOL; KETAMINE; LAMOTRIGINE; LITHIUM; MODAFINIL; MOOD STABILIZER; NEUROPEPTIDE; NEUROTROPHIC FACTOR; NIMODIPINE; OMEGA 3 FATTY ACID; PLACEBO; RILUZOLE; RIMONABANT; SODIUM CHANNEL BLOCKING AGENT; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN;

AFFECTIVE PSYCHOSIS; ANXIETY DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; ELECTROSTIMULATION; HUMAN; MAGNETIC STIMULATION; MAJOR DEPRESSION; MIGRAINE; NONHUMAN; PAIN; PANIC; POSTTRAUMATIC STRESS DISORDER; REVIEW; SLEEP DISORDER; SOCIAL PHOBIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

ANIMALS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEUROLOGY; NEUROPEPTIDES; NEUROPHARMACOLOGY; PSYCHIATRY; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 47749151087     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Perlis RH, Miyahara S, Marangell LB, et al; STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55:875-881.
2. Leverich GS, Post RM, Keck PE Jr, et al. The poor prognosis of childhood-onset bipolar disorder. J Pediatr. 2007;150:485-490.
3. Post RM, Kowatch RA.The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry. 2006;67:115-125.
4. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Child Psychiatric Workgroup on Bipolar Disorder. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213-235.
5. Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther. 2003;305:410-416.
6. Szuba MP, Amsterdam JD, Fernando AT 3rd, Gary KA, Whybrow PC, Winokur A. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol. 2005;25:325-330.
7. Yarbrough GG, Kamath J, Winokur A, Prange AJ Jr. Thyrotropin-releasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions. Med Hypotheses. 2007;69:1249-1256.
8. Frye MA, Gary KA, Marangell LB, et al. CSF thyrotropin-releasing hormone gender difference: implications forneurobiology and treatment of depression. J Neuropsychiatry Clin Neurosci. 1999;11:349-353.
9. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54:214-222.
10. Callahan AM, Frye MA, Marangell LB. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry. 1997;41:264-272.
11. Post RM, Weiss SR. Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic. Biol Psychiatry. 1992;32:469-484.
12. Post RM. Animal models of mood disorders: kindling as a model of affective illness progression. In: Schachter S, Holmes G, Kasteleijn-Nolst Trenité D, eds. Behavioral Aspects of Epilepsy: Principles and Practice. New York, NY: Demos Medical Publishing; 2007;19-27.
13. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoreticalimplications. J Psychiatr Res. 2007;41:979-990.
14. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat Stress. Science. 2006;10;311:864-868.
15. Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict. 2007;16:71-78.
16. Sackeim HA, Prudic J. Length of the ECT course in bipolar and unipolar depression. J ECT. 2005;21:195-197.
17. Sackeim HA, Prudic J, Fuller R, Keilp J, Lavori PW, Olfson M. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32:244-254.
18. Post RM, Speer AM. rTMS and related somatic therapies: prospects for the future. In: Belmaker RH, George MS, eds. TMS in Clinical Psychiatry. Washington DC: American Psychiatric Press, Inc; 2007.
19. O'Reardon JP, Solvason, HB, Janicak, PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62:1208-1216.
20. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60:369-375.
21. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355-363.
22. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;1;58:364-373.
23. Marangell LB, Martinez M, Jurdi RA, Zboyan H. Neurostimulation therapies in depression: a review of new modalities. Acta Psychiatr Scand. 2007;116:174-181.
24. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;3;45:651-660.
25. Holcomb RR, Worthington WB, McCullough BA. McClean MJ. Static magnetic field therapy for pain in the abdomen and genitals. Pediatr Neurol. 2000;23:261-264,
26. McLean MJ, Engstrom S, Holcomb RR. Magnetotherapy: Potential Therapeutic Benefits and Adverse Effects. New York, NY: TFG Press; 2003.
27. Segal NA, Toda Y, Huston J, et al. Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double blind clinical trial. Arch Phys Med Rehabil. 2001;82:1453-1460.
28. Rohan M, Parow A, Stoll AL. Low-field magnetic stimulation in bipolar depression using an MRI-based stimulator. Am J Psychiatry. 2004;161:93-98.
29. McLean MJ, Holcomb RR, Wamil AR, Pickett JD, Cavopol AV. Blockage of sensory neuron action potentials by a static magnetic field in the 10 mT range. Bioelectronmagnetics. 1995;16:20-32.
30. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;26;356:1711-1722.
31. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007;31:858-873.
32. Post RM, Leverich GS. The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: The need for earlier and alternative modes of therapeutic intervention. Dev Psychopathol. 2006; 18:1181-1211.
33. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C; Agomelatine Bipolar StudyGroup. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9:628-635.
34. Mouret,J, Lemoine P, Minuit MP, Benkelfat C, Renardet M. Effects of trazodone on the sleep of depressed subjects-a polysomnographic study. Psychopharmacology (Berlin). 1988;95(suppl):S37-S43.
35. Smith MI, Piper DC, Duxon MS, Upton N. Effect of SB-243213, a selective 5HT2c receptor antagonist on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav. 2002;71:599-605.
36. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691-696.
37. Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol Int. 2006;23:403-412.
38. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007;22 (suppl 2):S9-S14.
39. Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol. 2006;21(suppl 1):S17-S20.
40. Varcoe T, Kennaway DJ, Voultsios A. Activation of 5HT2c receptors acutely induces Per gene expression in the rat suprachiasmatic nucleus at night. Mol Brain Res. 2003;119:192-200.
41. Kennaway DJ, Moyer RW. Serotonin 5HT2C agonists mimic the effect of light pulses on circadian rhythms. Brain Res. 1998;806:257-270.
42. Baxter LR Jr, Liston EH, Schwartz JM, et al. Prolongation of the antidepressant response to partial sleep deprivation bylithium. Psychiatry Res. 1986;19:17-23.
43. Benedetti F, Dallaspezia S, Fulgosi MC, Barbini B, Colombo C, Smeraldi E. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiol Int. 2007;24:921-937.
44. Vawter MP, Rollins B, Morgan L, et al. The effect of total sleep deprivation on transcript expression in peripheral blood from health controls and mood disorder. Paper presented at: ACNP 46th Annual Meeting. Boca Raton, FI; 2007.
45. Zarate CA Jr, Singh JB, Carlson PJ, et al A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
46. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;15;57:430-432.
47. Charney DS. Rapid Antidepressant strategies: mechanism of action. Paper presented at: ACNP 46th Annual Meeting. Boca Raton, FI; 2007.
48. Preskorn, Baker, Omo, Kolluri, Menniti, Landen. A placebo-controlled trial of the NR2B specific NMDA antagonist CP-101, 606 plus paroxetine for treatment resistant depression (TRD). Paper presented at: 160th Annual American Psychiatric Association Meeting. San Diego, CA; 2007.
49. Hough CJ, Irwin RP, Gao XM, Rogawski MA, Chuang DM. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther. 1996;276:143-149.
50. Quinones, MP. Inflammation may play an important role in the pathogenesis of pediatric bipolar due to its negative effects on the structure and function of the prefrontal cortex. Paper presented at: CNP 46th Annual Meeting. Boca Raton, FI; 2007.
51. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104:91-95.
52. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implicartions for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32:675-692.
53. Harvey BH, Joubert C, du Preez JL, Berk M. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res. 2008;33:508-517.
54. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci. 2003;1003:349-351.
55. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652-657.
56. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005;19:59-65.
57. Coppen A, and Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60:121-130.
58. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159:477-479.
59. Keck PE Jr, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60:1020-1022.
60. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242-1249.
61. Post RM. What is an ideal mood stabilizer? Clin Approaches Bipolar Disord. 2006;5:14-21.
62. Antelman SM, Caggiula AR, Kiss S, Edwards D J, Kocan D, Stiller R. Neurochemical and physiological effects of cocaine oscillate with sequential drug treatment: possibly a major factor in drug variability. Neuropsychopharmacology. 1995;12:297-306.
63. Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein RP, Agam G. Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. Bipolar Disord. 2002;4:67-69.
64. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, orrisperidone. Am J Psychiatry. 2006;163:210-216.
65. Pazzaglia PJ, Post RM, Ketter TA, et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol. 1998;18:404-413.
66. Miklowitz DJ, Otto MW, Frank E, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry. 2007;164:1340-1347.